Exane Derivatives’s West Pharmaceutical WST Stock Holding History

Exane Derivatives’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-455	Closed	-$187K	–	1021
2022 Q1	$187K	Buy	+455	New	+$178K	0.05%	349
2021 Q4	–	Sell	-5	Closed	-$2.12K	–	1069
2021 Q3	$2.12K	Buy	+5	New	+$2.11K	﹤0.01%	802

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Exane Derivatives's WST Position: Q2 2022 in Review

Exane Derivatives sold out of West Pharmaceutical (WST) in Q2 2022, closing a stake of 455 shares — an estimated $187K sold.

Exane Derivatives first reported a position in WST in Q3 2021 and held it in 2 quarters. The position peaked at $187K in Q1 2022. 655 funds tracked by Wall St. Rank hold WST as of Q2 2022.

Exane Derivatives reported no remaining West Pharmaceutical position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 455 West Pharmaceutical shares in Q2 2022, an estimated $187K.
Exane Derivatives first reported a position in West Pharmaceutical in Q3 2021 and held it in 2 quarters.
Exane Derivatives's West Pharmaceutical position peaked at $187K in Q1 2022.
655 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.